Composition:
Dapagliflozin 10 mg ,Sitagliptin 100 mg ,Metformin Hydrochloride (XR) 500 mg
Therapeutic Class: Antidiabetic (Triple Oral Hypoglycemic Combination)
Dapaking Trio XR is a triple-drug fixed-dose combination used in the management of Type 2 Diabetes Mellitus (T2DM). It combines three agents with complementary mechanisms:
Dapagliflozin: A SGLT2 inhibitor that lowers blood glucose by promoting urinary glucose excretion.
Sitagliptin: A DPP-4 inhibitor that enhances incretin activity, increasing insulin release and decreasing glucagon secretion.
Metformin XR: A biguanide that reduces hepatic glucose production and improves insulin sensitivity.
Together, they provide comprehensive glycemic control with a reduced risk of hypoglycemia and additional cardiovascular and renal benefits.
Warnings and Precautions
Lactic Acidosis Risk (Metformin): Avoid in renal impairment or hypoxic conditions.
Genital/Mycotic Infections (Dapagliflozin): Maintain good hygiene; monitor for infections.
Pancreatitis (Sitagliptin): Discontinue if symptoms occur.
Volume Depletion: Monitor blood pressure and renal function, especially in elderly or diuretic-treated patients.
Hypoglycemia: May occur when combined with insulin or sulfonylureas.
Adverse Effects
Common:
Urinary tract infections, genital infections, nausea, diarrhea, headache, dyspepsia.
Serious:
Lactic acidosis (rare)
Pancreatitis (rare)
Hypersensitivity reactions
Hypotension or dehydration
Storage
Store below 30°C, protected from moisture and light.
Keep out of reach of children
